{"id":"d745-formulation-i","safety":{"commonSideEffects":[{"rate":null,"effect":"Common adverse event"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The exact mechanism of action of D745 formulation I is not well understood, but it is believed to work by interacting with the molecular target, leading to a therapeutic effect.","oneSentence":"D745 formulation I is a small molecule that targets the molecular target.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:08:29.146Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Indication 1"}]},"trialDetails":[{"nctId":"NCT05566028","phase":"PHASE3","title":"The Efficacy and Safety of D745 Added to D150 Plus D759 Therapy in Patients with Type 2 Diabetes","status":"COMPLETED","sponsor":"Chong Kun Dang Pharmaceutical","startDate":"2022-10-12","conditions":"Type 2 Diabetes","enrollment":172}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"D745 formulation I","genericName":"D745 formulation I","companyName":"Chong Kun Dang Pharmaceutical","companyId":"chong-kun-dang-pharmaceutical","modality":"Small molecule","firstApprovalDate":"","aiSummary":"D745 formulation I is a small molecule that targets the molecular target. Used for Indication 1.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}